How can we improve the translational landscape for a faster cure of type 1 diabetes?

Journal of Clinical Investigation

Volumn 119, Issue 5, 2009, Pages 1061-1065

  Von Herrath, Matthias ^a   Chan, Andrew ^b  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD3 ANTIBODY; GLUTAMATE DECARBOXYLASE; IMMUNOMODULATING AGENT; INSULIN;

BIOMEDICINE; COMMUNITY; DISEASE COURSE; DRUG COST; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; LICENSING; MEDICAL INFORMATION; MEDICAL PRACTICE; MEDICAL RESEARCH; MEDICINE; MONOTHERAPY; MOUSE STRAIN; PRIORITY JOURNAL; PROGNOSIS; SAFETY; SHORT SURVEY; THERAPY EFFECT; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; ARTICLE; COOPERATION; DRUG COMBINATION; DRUG DEVELOPMENT; ECONOMICS; HEALTH CARE ORGANIZATION; INTERPERSONAL COMMUNICATION; ORGANIZATION; PATENT; TIME;

ACADEMIES AND INSTITUTES; COMMUNICATION; COOPERATIVE BEHAVIOR; DIABETES MELLITUS, TYPE 1; DRUG DISCOVERY; DRUG INDUSTRY; DRUG THERAPY, COMBINATION; HUMANS; INTELLECTUAL PROPERTY; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; TIME FACTORS;

EID: 66449123727     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI37593     Document Type: Short Survey

References (13)

1. NIH. 2000. Report of the Autoimmune Diseases Coordinating Committee. October 2000. http://www3.niaid.nih.gov/topics/autoimmune/PDF/adccrev.pdf.
2. Akinbami, L. 2006. Asthma prevalence, health care use and mortality: United States, 2003-05. http://www.cdc.gov/nchs/products/pubs/pubd/hestats/ ashtma03-05/asthma03-05.htm.
3. Dantal, J., and Soulillou, J.P. 2005. Immunosuppressive drugs and the risk of cancer after organ transplantation. N. Engl. J. Med. 352:1371-1373.
4. Scandling, J.D., et al. 2008. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N. Engl. J. Med. 358:362-368.
5. DiMasi, J.A., Hansen, R.W., and Grabowski, H.G. 2003. The price of innovation: new estimates of drug development costs. J. Health Econ. 22:151-185.
6. Rossini, A.A. 2007. Passing the baton - to whom? J. Clin. Invest. 117:285-288.
7. Innovative Medicines Initiative website. http://imi.europa.eu/index-en. html.
8. Kamel, N., Compton, C., Middelveld, R., Higenbottam, T., and Dahlen, S.E. 2008. The Innovative Medicines Initiative (IMI): a new opportunity for scientific collaboration between academia and industry at the European level. Eur. Respir. J. 31:924-926.
9. National Center for Research Resources. 2009. Clinical and Translational Science Awards. http://www.ncrr.nih.gov/clinical-research-resources/clinical- and-translational-science-awards/.
10. United States Food and Drug Administration. 2007. Food and Drug Administration Amendments Act of 2007. http://www.fda.gov/cder/regulatory/FDAAA/ default.htm.
11. United States Food and Drug Administration. 2008. Celebrating the successes of the Orphan Drug Act. http://www.fda.gov/consumer/updates/oda020808. html.
12. Bresson, D., et al. 2006. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J. Clin. Invest. 116:1371-1381.
13. NIH Autoimmune Diseases Coordinating Committee. 2002. Autoimmune diseases research plan. http://www.niaid.nih.gov/dait/pdf/ADCC-Report.pdf.